Alogliptin vs Linagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Alogliptin · Nesina
Marketed by Takeda Pharmaceutical Company and partners
NCT00286429 · Phase 3 · completed
The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.
Next expected readout: December 2026 · NCT07093476 (registry estimate)
Reported efficacy
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)
Result source: NCT02856113
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
Reported efficacy
The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)
Result source: NCT01243424
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alogliptin | Linagliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.1%−0.6 vs placeboNCT00286429285 other results
| -0.6% vs 0.1%−0.6 vs placeboNCT00954447129 other results
|
| Body weight, change (kg) | 0.6 vs 0.6±0 vs placeboNCT00286429111 other results
| 1.4 vs -0.0+1.5 vs placeboNCT034295434 other results
|
| HbA1c below 7% | 63.3% vs 30%+33.3 vs placeboNCT012891192 other results
| 26.9% vs 24.5%+2.4 vs placeboNCT034295437 other results
|
| Fasting plasma glucose, change | -0.7 vs 0.3−1 vs placeboNCT00286429351 other results
| -0.1 vs 0.0−0.2 vs placeboNCT0095444795 other results
|
| 3-point MACE (% with event) | 11.3% vs 11.8%−0.5 vs placeboNCT00968708 | 20.7% vs 21.2%vs GlimepirideNCT012434242 other results
|
HbA1c, change
- Alogliptin
- -0.7% vs -0.1%−0.6 vs placeboNCT00286429
285 other results
- -0.6% vs -0.0% NCT00286455
- 0.1% vs -0.0% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.1% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.6% vs -0.1% NCT00286429
- -0.6% vs -0.0% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.6% vs -0.1% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.6% vs 0.1% NCT01023581
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -1.0% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.6% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -0.9% vs -0.4% NCT00432276
- -1.0% vs 0.0% NCT01263483
- -1.7% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.6% NCT00856284
- -0.7% vs 0.3% NCT01318083
- -1.0% vs -0.2% NCT01318070
- -0.9% vs 0.0% NCT01263483
- -1.6% vs -1.1% NCT00395512
- -0.6% vs 0.3% NCT01318083
- -0.9% vs -0.2% NCT01318070
- 0.3% vs 0.8% NCT02856113
- 0.1% vs 0.5% NCT02856113
- -0.7% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -1.0% vs -0.2% NCT00328627
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.2% vs -0.2% NCT02856113
- -0.8% vs -0.2% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.4% vs -0.3% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.3% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.5% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.6% vs -0.3% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.3% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.5% vs -0.1% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.2% NCT00328627
- -0.7% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.3% NCT00286494
- -0.7% vs -0.1% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.5% vs -0.3% NCT00286429
- -0.4% vs -0.1% NCT00286455
- -0.4% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.4% vs -0.1% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -1.4% vs -0.2% NCT00328627
- -1.5% vs -0.2% NCT00328627
- -1.7% vs -0.2% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.7% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.2% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.4% vs -0.2% NCT00328627
- -1.4% vs -0.2% NCT00328627
- -1.6% vs -0.2% NCT00328627
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.4% vs 0.1% NCT01023581
- -1.2% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.1% vs 0.1% NCT01023581
- -1.2% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -0.7% vs 0.1% NCT01023581
- -0.8% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.6% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -1% vs -1.2% NCT00395512
- -1.0% vs -1.2% NCT00395512
- -1.0% vs -1.0% NCT00395512
- -0.8% vs -0.7% NCT00395512
- -0.6% vs -0.3% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.9% vs -0.5% NCT00432276
- -0.7% vs -0.0% NCT01263483
- -0.4% vs -0.0% NCT01263483
- -0.2% vs -0.0% NCT01263483
- -1.7% vs -1.2% NCT00395512
- -0.8% vs -0.8% NCT00856284
- -0.9% vs -0.4% NCT00432276
- -1.7% vs -1.2% NCT00395512
- -0.7% vs -0.8% NCT00856284
- -0.8% vs -0.3% NCT00432276
- -1.6% vs -1.0% NCT00395512
- -0.6% vs -0.7% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -1.2% vs -0.7% NCT00395512
- -0.4% vs -0.4% NCT00856284
- -0.6% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.4% vs -0.1% NCT00432276
- -0.8% vs -0.0% NCT01263483
- -0.6% vs -0.3% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.6% vs -0.7% NCT00856284
- -0.4% vs -0.4% NCT00856284
- -0.4% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.4% vs -0.0% NCT01263483
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.2% vs -0.0% NCT01263483
- -1.5% vs -1.2% NCT00395512
- -1.4% vs -1.2% NCT00395512
- -1.3% vs -1.0% NCT00395512
- -1.0% vs -0.7% NCT00395512
- -0.5% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.5% vs -0.3% NCT00395512
- -0.3% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.6% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.7% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.4% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.2% vs -0.0% NCT00755846
- -0.5% vs 0.1% NCT01263470
- -0.7% vs 0% NCT01263470
- -0.4% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.6% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.7% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.1% vs 0% NCT01263470
- -0.5% vs 0% NCT01263470
- -0.1% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.7% vs -0.4% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.6% vs -0.2% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.5% vs -0.2% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.9% vs -0.1% NCT01263496
- -0.9% vs -0.2% NCT01263496
- -0.5% vs -0.4% NCT01263496
- -0.4% vs -0.4% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.4% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.1% NCT01263496
- -0.4% vs -0.2% NCT01263496
- Linagliptin
- -0.6% vs 0.1%−0.6 vs placeboNCT00954447
129 other results
- -0.7% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.6% vs -0.0% NCT01792518
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.5% vs -0.1% NCT01087502
- -1.1% vs -0.6% NCT00641043
- -0.4% vs 0.3% NCT00621140
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.7% vs 0.1% NCT01734785
- -0.6% vs -0.2% NCT02897349
- -0.4% vs -0.7% NCT01183013
- 0.3% vs -0.2% NCT03429543
- -1.3% vs -1.6% NCT01708902
- -1.3% vs -1.7% NCT01708902
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -2.1% vs -1.6% NCT01708902
- -2.3% vs -1.6% NCT01708902
- -2.2% vs -1.7% NCT01708902
- -2.4% vs -1.7% NCT01708902
- -0.5% vs 0.1% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.5% vs 0% NCT00954447
- -0.8% vs -0.1% NCT00602472
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.2% NCT01215097
- -0.7% vs -0.2% NCT01214239
- -0.6% vs -0.1% NCT01215097
- -0.9% vs -0.4% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.6% vs -0.1% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.7% vs -0.2% NCT01194830
- -0.6% vs -0.0% NCT01084005
- -0.5% vs -0.1% NCT01214239
- -0.5% vs -0.0% NCT01215097
- -0.6% vs -0.2% NCT00996658
- -0.5% vs 0.1% NCT00601250
- -0.4% vs -0.1% NCT01084005
- -1.1% vs -0.6% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.8% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.8% vs -0.3% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.7% vs -0.2% NCT00602472
- -0.4% vs 0.1% NCT00601250
- -0.4% vs -0.0% NCT00641043
- -0.4% vs 0.1% NCT00621140
- -0.6% vs -0.2% NCT01194830
- -0.5% vs 0.1% NCT03429543
- 0.1% vs 0.1% NCT01243424
- -0.4% vs -0.3% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.5% vs -0.4% NCT01087502
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.6% NCT01183013
- -0.5% vs -0.3% NCT01087502
- -0.4% vs -0.4% NCT01183013
- -0.5% vs -0.1% NCT01087502
- -0.5% vs -0.1% NCT01087502
- -0.2% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT01087502
- -0.9% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.2% vs -0.7% NCT01183013
- -0.8% vs -0.6% NCT01183013
- -1.1% vs -0.6% NCT01183013
- -1.2% vs -0.6% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -1.0% vs -0.4% NCT01183013
- -0.4% vs -0.2% NCT01183013
- -0.5% vs -0.2% NCT01183013
- -0.6% vs -0.2% NCT01183013
- -1.3% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -1.4% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -1.4% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.6% vs -1.2% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.0% vs -0.4% NCT02240680
- -0.5% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -1.0% vs -1.0% NCT01438814
- -0.6% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.8% vs -0.8% NCT01438814
- -0.3% vs -0.3% NCT01438814
- 7.6% vs 8% NCT02004366
- 6.6% vs 8% NCT02004366
- 7% vs 8% NCT02004366
- 8.6% vs 8% NCT02004366
Body weight, change (kg)
- Alogliptin
- 0.6 vs 0.6±0 vs placeboNCT00286429
111 other results
- -0.2 vs 0.2 NCT00286455
- -0.7 vs -0.7 NCT00328627
- 1.1 vs 1.0 NCT00286494
- -0.7 vs -0.4 NCT00286442
- 0.7 vs -0.2 NCT00286468
- 0.5 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.5 vs -0.6 NCT00328627
- 0.9 vs 0.9 NCT00286494
- -0.6 vs -0.4 NCT00286442
- 0.6 vs -0.3 NCT00286468
- 0.3 vs 0.5 NCT00286429
- 0.1 vs -0.3 NCT00286455
- -0.6 vs -0.5 NCT00328627
- 0.6 vs 0.6 NCT00286494
- -0.6 vs -0.6 NCT00286442
- 0.4 vs -0.1 NCT00286468
- 0.2 vs 0.4 NCT00286429
- -0.0 vs -0.4 NCT00286455
- -0.5 vs -0.1 NCT00328627
- 0.4 vs 0.4 NCT00286494
- -0.5 vs -0.1 NCT00286442
- 0.3 vs -0.3 NCT00286468
- 0.7 vs 0.6 NCT00286429
- -0.1 vs 0.2 NCT00286455
- -0.0 vs -0.7 NCT00328627
- 1.5 vs 1.0 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.6 vs -0.2 NCT00286468
- 0.6 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.1 vs -0.6 NCT00328627
- 1.1 vs 0.9 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.8 vs -0.3 NCT00286468
- 0.4 vs 0.5 NCT00286429
- -0.4 vs -0.3 NCT00286455
- -0.1 vs -0.5 NCT00328627
- 0.7 vs 0.6 NCT00286494
- -0.3 vs -0.6 NCT00286442
- 0.6 vs -0.1 NCT00286468
- 0.1 vs 0.4 NCT00286429
- 0.0 vs -0.4 NCT00286455
- -0.1 vs -0.1 NCT00328627
- 0.5 vs 0.4 NCT00286494
- -0.3 vs -0.1 NCT00286442
- 0.5 vs -0.3 NCT00286468
- 1.3 vs -0.7 NCT00328627
- 2.1 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 0.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 0.4 vs -0.5 NCT00328627
- 1.0 vs -0.5 NCT00328627
- 1.1 vs -0.5 NCT00328627
- 0.2 vs -0.1 NCT00328627
- 0.7 vs -0.1 NCT00328627
- 0.9 vs -0.1 NCT00328627
- 1.3 vs -0.7 NCT00328627
- 1.9 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 1.0 vs -0.6 NCT00328627
- 1.4 vs -0.6 NCT00328627
- 1.9 vs -0.6 NCT00328627
- 0.2 vs -0.5 NCT00328627
- 0.6 vs -0.5 NCT00328627
- 0.9 vs -0.5 NCT00328627
- 0.1 vs -0.1 NCT00328627
- 0.5 vs -0.1 NCT00328627
- 0.4 vs -0.1 NCT00328627
- -0.9 vs -1.6 NCT01289119
- -0.8 vs -1.6 NCT01289119
- -0.1 vs -1.6 NCT01289119
- -0.7 vs -1.0 NCT01289119
- -0.4 vs -1.0 NCT01289119
- -0.1 vs -1.0 NCT01289119
- -0.7 vs 0.9 NCT00856284
- 0.7 vs 1.0 NCT00432276
- -0.9 vs 1.0 NCT00856284
- -0.5 vs 0.7 NCT00856284
- 0.3 vs 0.6 NCT00432276
- 1.1 vs 1.5 NCT00432276
- 0.3 vs 0.5 NCT00432276
- 0.2 vs 0.3 NCT00432276
- -0.9 vs 0.9 NCT00856284
- 1.1 vs 1.6 NCT00432276
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.6 vs 1.0 NCT00856284
- -0.5 vs 0.7 NCT00856284
- -0.6 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.8 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.3 vs 2.2 NCT00395512
- -0.5 vs 1.6 NCT00395512
- -0.8 vs 1.0 NCT00395512
- -0.3 vs 0.6 NCT00395512
- 3.1 vs 2.2 NCT00395512
- 2.4 vs 1.6 NCT00395512
- 1.4 vs 1.0 NCT00395512
- 0.8 vs 0.6 NCT00395512
- 2.5 vs 2.2 NCT00395512
- 1.9 vs 1.6 NCT00395512
- 1.2 vs 1.0 NCT00395512
- 0.7 vs 0.6 NCT00395512
- Linagliptin
- 1.4 vs -0.0+1.5 vs placeboNCT03429543
4 other results
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 2.7 vs -0.0 NCT03429543
- -0.4 vs -1.1 NCT01438814
HbA1c below 7%
- Alogliptin
- 63.3% vs 30%+33.3 vs placeboNCT01289119
2 other results
- 55.1% vs 30% NCT01289119
- 61.7% vs 30% NCT01289119
- Linagliptin
- 26.9% vs 24.5%+2.4 vs placeboNCT03429543
7 other results
- 13.9% vs 8.2% NCT02897349
- 16.7% vs 24.5% NCT03429543
- 43.6% vs 50% NCT01708902
- 72.1% vs 50% NCT01708902
- 77.1% vs 50% NCT01708902
- 33% vs 10% NCT01012037
- 34% vs 10% NCT01012037
Fasting plasma glucose, change
- Alogliptin
- -0.7 vs 0.3−1 vs placeboNCT00286429
351 other results
- -0.9 vs 0.6 NCT00286455
- -0.3 vs 0.7 NCT01023581
- -1.0 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.5 vs 0.1 NCT00286468
- -0.6 vs 0.5 NCT00286429
- -1.0 vs 0.4 NCT00286455
- -0.5 vs 0.5 NCT01023581
- -1.3 vs 0.4 NCT00328627
- -1.2 vs -0.4 NCT00286494
- -0.9 vs -0.0 NCT00286442
- -0.8 vs -0.0 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -1.0 vs 0.3 NCT00286455
- -0.4 vs 0.6 NCT01023581
- -1.3 vs 0.1 NCT00328627
- -1.3 vs -0.5 NCT00286494
- -0.8 vs 0.1 NCT00286442
- -0.7 vs -0.4 NCT00286468
- -0.2 vs -0.1 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -0.5 vs 0.6 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.5 vs -0.3 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -1.0 vs -0.2 NCT00286468
- -0.7 vs 0.3 NCT00286429
- -1.2 vs 0.2 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.2 NCT00286494
- -1 vs -0.0 NCT00286442
- -1.2 vs -0.2 NCT00286468
- -0.6 vs 0.1 NCT00286429
- -1.0 vs 0.2 NCT00286455
- -0.4 vs 0.3 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -1.2 vs -0.1 NCT00286468
- -0.6 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.2 vs 0.3 NCT01023581
- -1.0 vs 0.1 NCT00328627
- -1.0 vs -0.1 NCT00286494
- -0.7 vs -0.0 NCT00286442
- -1.1 vs 0.0 NCT00286468
- 0.1 vs 0.3 NCT00286429
- -0.6 vs 0.6 NCT00286455
- -0.5 vs 0.7 NCT01023581
- -0.7 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.3 vs 0.1 NCT00286468
- -0.2 vs 0.5 NCT00286429
- -0.7 vs 0.4 NCT00286455
- -0.7 vs 0.5 NCT01023581
- -0.5 vs 0.4 NCT00328627
- -1.2 vs -0.4 NCT00286494
- -1 vs -0.0 NCT00286442
- -0.5 vs -0.0 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -0.9 vs 0.1 NCT00328627
- -1.0 vs -0.5 NCT00286494
- -1.0 vs 0.1 NCT00286442
- -0.5 vs -0.4 NCT00286468
- -0.3 vs -0.1 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.1 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.7 vs 0.4 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.3 vs -0.3 NCT00286494
- -1.1 vs 0.0 NCT00286442
- -1.1 vs -0.2 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.9 vs 0.2 NCT00286455
- -0.9 vs 0.4 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.3 vs -0.2 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.2 vs 0.1 NCT00286429
- -0.8 vs 0.2 NCT00286455
- -0.6 vs 0.3 NCT01023581
- -1.2 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.9 vs -0.1 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.5 vs 0.3 NCT00286455
- -0.7 vs 0.3 NCT01023581
- -0.8 vs 0.1 NCT00328627
- -0.8 vs -0.1 NCT00286494
- -0.8 vs -0.0 NCT00286442
- -0.7 vs 0.0 NCT00286468
- -2.1 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -2.2 vs 0.4 NCT00328627
- -2.4 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -2.2 vs 0.1 NCT00328627
- -2.4 vs 0.1 NCT00328627
- -3.0 vs 0.1 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -2.9 vs 0.2 NCT00328627
- -2.2 vs 0.3 NCT00328627
- -2.5 vs 0.3 NCT00328627
- -2.9 vs 0.3 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2 vs 0.2 NCT00328627
- -2.6 vs 0.2 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.4 vs 0.1 NCT00328627
- -1.8 vs 0.7 NCT01023581
- -2.5 vs 0.7 NCT01023581
- -2.3 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -1.9 vs 0.5 NCT01023581
- -2.5 vs 0.5 NCT01023581
- -2.4 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.6 vs 0.4 NCT00328627
- -2.0 vs 0.6 NCT01023581
- -2.6 vs 0.6 NCT01023581
- -2.3 vs 0.1 NCT00328627
- -2.3 vs 0.1 NCT00328627
- -2.7 vs 0.1 NCT00328627
- -1.8 vs 0.6 NCT01023581
- -2.5 vs 0.6 NCT01023581
- -2.4 vs 0.2 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -1.8 vs 0.4 NCT01023581
- -2.4 vs 0.4 NCT01023581
- -2.4 vs 0.3 NCT00328627
- -2.3 vs 0.3 NCT00328627
- -2.4 vs 0.3 NCT00328627
- -2.1 vs 0.4 NCT01023581
- -2.5 vs 0.4 NCT01023581
- -2.0 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -1.9 vs 0.3 NCT01023581
- -2.4 vs 0.3 NCT01023581
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT01023581
- -2.0 vs 0.3 NCT01023581
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.2 vs -0.3 NCT01289119
- -1.2 vs -0.3 NCT01289119
- -0.9 vs 0.7 NCT00655863
- -0.9 vs 0.3 NCT00655863
- -1.1 vs -0.2 NCT00655863
- -2.1 vs 0.7 NCT00655863
- -2.1 vs 0.3 NCT00655863
- -2.2 vs -0.2 NCT00655863
- -1.1 vs -0.3 NCT01289119
- -1.1 vs -0.4 NCT01289119
- -1.3 vs -0.4 NCT01289119
- -1.2 vs -0.4 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.3 vs -0.3 NCT01289119
- -0.9 vs -0.3 NCT01289119
- -0.7 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -0.4 vs 0.1 NCT00856284
- -0.8 vs -0.2 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -0.5 vs -0.0 NCT00856284
- -0.3 vs 0.1 NCT00856284
- -0.8 vs -0.3 NCT00432276
- -0.6 vs -0.2 NCT00856284
- -0.3 vs 0.3 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.3 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -1 vs -0.3 NCT00432276
- -0.2 vs 0.3 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.6 vs -0.6 NCT00856284
- -1.0 vs -0.1 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -0.9 vs -0.0 NCT00432276
- -0.2 vs 0.3 NCT00856284
- -0.3 vs 0.1 NCT00856284
- -0.4 vs -0.0 NCT00856284
- -0.2 vs 0.1 NCT00856284
- -0.4 vs -0.2 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.4 vs -0.3 NCT00856284
- -0.5 vs -0.4 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -0.5 vs -0.5 NCT00856284
- -0.6 vs -0.6 NCT00856284
- -0.6 vs -0.4 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -1.4 vs -2.1 NCT00395512
- -1.6 vs -2.3 NCT00395512
- -1.5 vs -2.3 NCT00395512
- -1.6 vs -2.4 NCT00395512
- -1.6 vs -2.1 NCT00395512
- -1.5 vs -1.8 NCT00395512
- -0.9 vs -0.8 NCT00395512
- -0.8 vs -0.4 NCT00395512
- -1.1 vs -0.3 NCT01263483
- -1.1 vs -0.1 NCT01263483
- -0.9 vs -0.0 NCT01263483
- -0.9 vs -0.2 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -3 vs -2.3 NCT00395512
- -2.9 vs -2.3 NCT00395512
- -2.9 vs -2.4 NCT00395512
- -0.9 vs 0.3 NCT01318083
- -1.1 vs -0.1 NCT01318070
- -1.0 vs -0.3 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -1.0 vs 0.3 NCT01318083
- -1.2 vs -0.2 NCT01318070
- -1.2 vs -0.1 NCT01263483
- -2.3 vs -1.8 NCT00395512
- -1.3 vs 0.1 NCT01318083
- -1.0 vs -0.2 NCT01318070
- -1.3 vs -0.0 NCT01263483
- -1.9 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -1.0 vs -0.2 NCT01263483
- -1.5 vs -0.4 NCT00395512
- -2.7 vs -2.1 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -2.7 vs -2.4 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.8 vs -0.1 NCT01318070
- -2.7 vs -2.1 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -2.2 vs -1.8 NCT00395512
- -1.2 vs 0.1 NCT01318083
- -0.8 vs -0.2 NCT01318070
- -1.7 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.7 vs -0.2 NCT01318070
- -1.3 vs -0.4 NCT00395512
- -1.5 vs 0.5 NCT00755846
- -1.0 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT01263470
- -1.4 vs 0.3 NCT00755846
- -1.1 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -0.3 vs 0.5 NCT00755846
- -0.8 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT01263470
- -0.6 vs 0.3 NCT00755846
- -1.2 vs 0.5 NCT01263470
- -0.9 vs 0.1 NCT01263470
- -1.2 vs 0.5 NCT00755846
- -1.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT00755846
- -1.3 vs 0.3 NCT01263470
- -1.3 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT00755846
- -1.3 vs 0.5 NCT01263470
- -1.2 vs 0.1 NCT01263470
- -0.4 vs 0.5 NCT00755846
- -0.5 vs 0.3 NCT01263470
- -0.7 vs 0.3 NCT01263470
- -0.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -1.2 vs -0.7 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.4 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.9 vs -0.2 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -1.1 vs -0.7 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -1.0 vs -0.8 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.7 vs -0.4 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.8 vs -0.2 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -1.4 vs -0.7 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.2 vs -0.5 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.1 vs -0.4 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.1 vs -0.3 NCT01263496
- -1.0 vs -0.4 NCT01263496
- -1.3 vs -0.2 NCT01263496
- -1.5 vs -0.5 NCT01263496
- -0.8 vs -0.7 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.5 vs -0.4 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.6 vs -0.3 NCT01263496
- -0.6 vs -0.4 NCT01263496
- -0.7 vs -0.2 NCT01263496
- -0.6 vs -0.5 NCT01263496
- Linagliptin
- -0.1 vs 0.0−0.2 vs placeboNCT00954447
95 other results
- -0.4 vs -0.2 NCT00954447
- -0.3 vs -0.1 NCT00954447
- -0.4 vs 0.3 NCT00954447
- -0.3 vs 0.2 NCT00954447
- -0.3 vs 0.5 NCT00602472
- -0.5 vs 0.1 NCT01214239
- -0.6 vs -0.1 NCT01215097
- -0.4 vs 0 NCT00954447
- -0.2 vs 0.1 NCT00954447
- -0.6 vs 0.0 NCT00996658
- -0.6 vs 0.6 NCT00601250
- -0.3 vs 0.4 NCT00602472
- -0.6 vs 0.6 NCT00601250
- -0.5 vs 0.3 NCT00602472
- -0.7 vs 0.2 NCT00601250
- -0.6 vs 0.3 NCT00602472
- -0.7 vs 0.3 NCT00601250
- -1.3 vs -0.6 NCT01194830
- -0.6 vs 0.6 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.7 vs -0.1 NCT01215097
- -0.5 vs -0.1 NCT00996658
- -0.7 vs 0.5 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.8 vs -0.3 NCT01215097
- -0.4 vs -0.0 NCT00954447
- -0.4 vs 0.2 NCT00996658
- -0.8 vs 0.4 NCT01084005
- -0.7 vs -0.0 NCT01214239
- -0.9 vs 0.3 NCT01215097
- -0.2 vs 0.7 NCT00996658
- -0.8 vs 0.3 NCT01084005
- -1.8 vs 0.3 NCT01734785
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.0 NCT00641043
- -0.5 vs 0.8 NCT00621140
- -1.8 vs -1.1 NCT00641043
- -0.4 vs 0.7 NCT00621140
- -1.9 vs -1.1 NCT00641043
- -0.6 vs 0.6 NCT00621140
- -1.9 vs -0.9 NCT00641043
- -0.6 vs 0.4 NCT00621140
- 0.2 vs -0.2 NCT01087502
- -0.1 vs -0.1 NCT01087502
- -0.1 vs -0.0 NCT01087502
- -0.1 vs -0.6 NCT01087502
- -0.1 vs -1.6 NCT01183013
- 0 vs -1.4 NCT01183013
- -0.5 vs -0.5 NCT01087502
- -0.8 vs -1.7 NCT01708902
- -0.3 vs -1.2 NCT01183013
- -0.7 vs -0.5 NCT01087502
- -0.3 vs -0.5 NCT01087502
- -0.4 vs -1.1 NCT01183013
- -0.4 vs -1.2 NCT01183013
- 0.0 vs 0.5 NCT01087502
- -0.3 vs 0.3 NCT01087502
- -0.6 vs 0.5 NCT01087502
- -0.2 vs -0.9 NCT01183013
- -0.6 vs 0.5 NCT01087502
- -1.1 vs -1.6 NCT01183013
- -1.5 vs -1.6 NCT01183013
- -1.9 vs -1.6 NCT01183013
- -1 vs -1.4 NCT01183013
- -1.5 vs -1.4 NCT01183013
- -1.9 vs -1.4 NCT01183013
- -0.9 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.1 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1 vs -1.2 NCT01183013
- -1.7 vs -1.2 NCT01183013
- -1.6 vs -1.2 NCT01183013
- -1.1 vs -0.9 NCT01183013
- -1.5 vs -0.9 NCT01183013
- -1.6 vs -0.9 NCT01183013
- -0.4 vs -0.3 NCT00915772
- -0.6 vs -0.3 NCT00915772
- -0.5 vs -0.4 NCT00915772
- -0.7 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -2.2 vs -1.7 NCT01708902
- -2.6 vs -1.7 NCT01708902
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.8 vs -0.2 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.6 vs -0.2 NCT00915772
- -1.2 vs -0.2 NCT01012037
- -0.9 vs -0.2 NCT01012037
- -1.4 vs -1.5 NCT01438814
3-point MACE (% with event)
- Alogliptin
- 11.3% vs 11.8%−0.5 vs placeboNCT00968708
- Linagliptin
- 20.7% vs 21.2%vs GlimepirideNCT01243424
2 other results
- 11.8% vs 12% NCT01243424
- 12.4% vs 12.1% NCT01897532
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. Alogliptin: 15 of 15 rows · Linagliptin: 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alogliptin Rows use multiple source trials | Linagliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,b,c NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted show 3 more doses-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted -0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted -0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted | -1.68 mmol/L @ 24wk*5 mga,b,c NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted show 3 more doses-1.67 mmol/L @ 24wk*5 mg NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted |
| Glycemic Rescue responder rate · % of participants | 12.8% (n=125) vs 32.8% (n=125) placebo25 mga,c,d NCT00328627 · Phase 3 · registry result, not featured evidence show 7 more doses14.5% (n=124) vs 32.8% (n=125) placebo12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9% (n=129) vs 32.8% (n=125) placebo25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.9% (n=123) vs 32.8% (n=125) placebo25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.6% (n=125) vs 32.8% (n=125) placebo25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.7% (n=129) vs 32.8% (n=125) placebo12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.8% (n=126) vs 32.8% (n=125) placebo12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.4% (n=127) vs 32.8% (n=125) placebo12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination | 7.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk5 mg QDa,c,d NCT01708902 · Phase 3 · registry result, not featured evidence show 2 more doses2.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4% (n=142) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.7% (n=145) @ 24wk25 mg QD and 1-6 mg QD or BIDa,b,c NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination show 3 more doses-0.78% (n=134) @ 24wk25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination -0.59% (n=137) @ 24wk12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination -0.68% (n=135) @ 24wk12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination | -2.02% (n=113) @ 24wk5 mga,b,c NCT01512979 · Phase 4 · registry result, not featured evidence show 3 more doses-2.01% (n=113) @ 24wk5 mg NCT01512979 · Phase 4 · registry result, not featured evidence -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c 6.5 or Less event count · % of participants | 2.3% (n=129) vs 0% (n=129) placebo @ 26wk*25 mg QDa,c,e,f NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted show 1 more dose2.3% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted | 7.4% (n=618) vs 1.9% (n=617) placebo @ 52wk*5 mgc,e,f NCT00954447 · Phase 3 · registry result, not featured evidence · converted to % from 46 Participants as posted |
| HbA1c 7.0 or Less event count · % of participants | 7.8% (n=129) vs 0.8% (n=129) placebo @ 26wk*25 mg QDa,c,e,f NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 10 participants as posted show 1 more dose8.4% (n=131) vs 0.8% (n=129) placebo @ 26wk*12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted | 17.6% (n=618) vs 7.1% (n=617) placebo @ 52wk*5 mgc,e,f NCT00954447 · Phase 3 · registry result, not featured evidence · converted to % from 109 Participants as posted |
| HbA1c Decrease 0 5 responder rate · % of participants | 60.9% (n=404) vs 37.6% (n=399) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metforminc,e,g NCT00432276 · Phase 3 · registry result, not featured evidence · combination | 55.4% (n=101) vs 36% (n=100) placebo @ 24wkc,e,g NCT02897349 · Phase 3 · registry result, not featured evidence |
| HbA1c Decrease 0.5 event count · % of participants | 54.3% (n=129) vs 31% (n=129) placebo @ 26wk*25 mg QDa,h,c,i NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted show 1 more dose53.4% (n=131) vs 31% (n=129) placebo @ 26wk*12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted | 21.1% (n=171) vs 15.9% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bida,h,c,i NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 36 participant as posted show 1 more dose21.8% (n=225) vs 15.9% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 49 participant as posted |
| HbA1c Less Than 6 5 responder rate · % of participants | 36.7% (n=90) vs 12.2% (n=90) placebo @ 16wka,c,j NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy show 2 more doses21.4% (n=98) vs 12.2% (n=90) placebo @ 16wk NCT01289119 · Phase 3 · registry result, not featured evidence · combination 30% (n=60) vs 12.2% (n=90) placebo @ 16wk NCT01289119 · Phase 3 · registry result, not featured evidence · combination | 15.4% (n=52) vs 9.4% (n=53) placebo @ 26wk5 mga,c,j NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk5 mg NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| HbA1c Less Than 7% event count · % of participants | 44.4% (n=207) vs 18.3% (n=104) placebo @ 26wk*25 mg QDa,h,c,e,i NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 92 participants as posted show 1 more dose51.6% (n=213) vs 18.3% (n=104) placebo @ 26wk*12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 110 participants as posted | 39.2% (n=171) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bida,h,c,e,i NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 67 participant as posted show 1 more dose25.3% (n=225) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 57 participant as posted |
| PPG 2h Change mg/dL absolute change · mmol/L | 3.08 vs 3.14 Voglibose mmol/L @ 24wk*25 mg QDa,k,c,e NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted show 7 more doses3.35 vs 2.92 Voglibose mmol/L*25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 60.4 mg/dL as posted 3.08 vs 3.14 Voglibose mmol/L @ 24wk*12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted 3.54 vs 2.92 Voglibose mmol/L*12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 63.8 mg/dL as posted 3.1 vs 3.14 Voglibose mmol/L @ 24wk*50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.9 mg/dL as posted 2.92 vs 2.92 Voglibose mmol/L*50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 52.6 mg/dL as posted 3.57 vs 3.14 Voglibose mmol/L @ 24wk*6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 64.3 mg/dL as posted 3.61 vs 2.92 Voglibose mmol/L*6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65 mg/dL as posted | -2.71 vs 1.01 placebo mmol/L @ 24wk*k,c,e NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -48.86 mg/dL as posted 3 other source trials-1.78 vs 0 placebo mmol/L @ 24wk* NCT02897349 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -32.01 mg/dL as posted -2.15 vs -2.04 placebo mmol/L @ 24wk*5 mg NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -38.74 mg/dL as posted -1.86 vs 1.38 placebo mmol/L @ 24wk* NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.51 mg/dL as posted |
| Triglyceride Change mg/dL absolute change · mg/dL | -16.4 vs -7.8 Pioglitazone 45 mg + Metformin mg/dL @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metforminc,e,l NCT00432276 · Phase 3 · registry result, not featured evidence · combination | 1.7 vs 5.2 Glimepiride mg/dL @ 432wkc,e,l NCT01243424 · Phase 3 |
| Dropout rate | 40.3%25 mg QDm NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results36.6%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.3%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 21.1%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 11% NCT00968708 · Phase 3 14.9% NCT01456130 · Phase 3 · registry result, not featured evidence 44.3%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 46.4%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.8%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 6.1%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 36.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 38.8%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 20.5%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 37.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 17.1%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 0%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 4.5%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 21.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 24.2%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 15.4%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.1%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.3%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 11.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 10.8%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 23.2%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 17.1%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 23.2%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 19.6%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 22.3%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 21.4%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 17.4%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 25.3%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 24.6%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1.9%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 5.7%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 2.6%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 6.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 3.8%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 3.8%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 6.3%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 28.9%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 27.3%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 31.1%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 12.5%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 7.3%n NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results7.5% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.3% NCT01243424 · Phase 3 0% NCT02467478 · Phase 4 · registry result, not featured evidence 15%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 24% NCT01897532 · Phase 4 · registry result, not featured evidence 5.3%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 20% NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 14%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 11.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 4.1%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.8%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 9.9%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 11.6%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 9.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 10.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 22.2%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 28.6%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 33.8%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 27.8%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 6.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 9%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 6.8%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 11.3%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 2.4%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 3.7%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 12.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 6.8%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.7%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 24.5%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.9%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 17%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 20.4%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 21.2% NCT00740051 · Phase 3 · registry result, not featured evidence 5.8% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 5.4% NCT00621140 · Phase 3 · registry result, not featured evidence 4.5%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 7.2%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.7%25 mg QDm NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results0.8%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.3%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 5.6% NCT00968708 · Phase 3 6% NCT01456130 · Phase 3 · registry result, not featured evidence 8.4%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 6.8%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 1.1%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 2%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 0%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.2%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 7.4%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 3.6%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 6.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 4.5%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination —25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence —25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 1.6%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 1.5%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.1%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.8%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.8%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 3.7%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3.7%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 4.1%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 3.3%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 3%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 3.8%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 3.8%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 1.2%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 4.4%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 6.8%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 2.9%n NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results1.7% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 — NCT01243424 · Phase 3 — NCT02467478 · Phase 4 · registry result, not featured evidence —5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 10.3% NCT01897532 · Phase 4 · registry result, not featured evidence 4%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination — NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.3%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.9%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 2.2%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 4.2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 4.8%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 3.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.9%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 4.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 3.4%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 2%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 1.5%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.7%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 1.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.4%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 4%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.8%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 4.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 2.6% NCT00740051 · Phase 3 · registry result, not featured evidence 1.5% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT00621140 · Phase 3 · registry result, not featured evidence 1.3%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 3.6%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.4%25 mg QDm NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results6.1%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.8%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.7%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 33.6% NCT00968708 · Phase 3 9% NCT01456130 · Phase 3 · registry result, not featured evidence 11%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.9%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 2.2%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 0%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 1.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 16.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 16.7%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 0.9%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 3.6%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 1.9%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 8%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 13.6%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 4.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.6%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.3%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.6%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 4.9%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 0.6%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 6.5%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.5%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 3.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2.8%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 5.6%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 5.4%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 2%25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 3.4%25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 10.7%12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 4.9%12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 2.9%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 1.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 8.2%25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 7.9%12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 5.2%50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 2.1%6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.4%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 2.4%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 10%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 3.2%n NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results3.4% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.4%5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 46.4% NCT01243424 · Phase 3 7.1% NCT02467478 · Phase 4 · registry result, not featured evidence 0%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 37% NCT01897532 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 12.6%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 25%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0.8%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence 13%Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence 15.1%Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 23.1%Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 15% NCT02350478 · Phase 4 · registry result, not featured evidence 5.3% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.6%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 9.6% NCT02897349 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 9.3%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 3.2%5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.5%2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 0.7%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.1%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.3%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 24.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 0.5%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 2%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.2%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 8.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.8%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.6%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.7%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0.9%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.8%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.3%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 8.6%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 0.7% NCT00740051 · Phase 3 · registry result, not featured evidence 3.1% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 3% NCT00621140 · Phase 3 · registry result, not featured evidence 2.2%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 4%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg QDm urinary tract infection 7% (placebo 7.8%) diarrhoea 6.2% (placebo 5.4%) nasopharyngitis 6.2% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results12.5 mg QD arthralgia 6.9% (placebo 2.3%) urinary tract infection 6.1% (placebo 7.8%) headache 5.3% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 25 mg QD nasopharyngitis 7.6% (placebo 7.8%) headache 6.8% (placebo 4.7%) upper respiratory tract infection 4.5% (placebo 9.4%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 12.5 mg QD nasopharyngitis 9% (placebo 7.8%) headache 7.5% (placebo 4.7%) back pain 5.3% (placebo 4.7%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 25 mg headache 18.7% (placebo 10.5%) hyperglycaemia 12% (placebo 11.8%) diarrhoea 9.3% (placebo 9.2%) NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 renal impairment 7.5% (placebo 6.5%) hypertension 7.1% (placebo 7.4%) hypoglycaemia 6.2% (placebo 5.9%) NCT00968708 · Phase 3 nasopharyngitis 35.8% upper respiratory tract inflammation 11.9% arthralgia 7.5% NCT01456130 · Phase 3 · registry result, not featured evidence 25 mg upper respiratory tract infection 10.3% hypertension 7.6% nasopharyngitis 7.6% NCT00856284 · Phase 3 · registry result, not featured evidence · combination 12.5 mg upper respiratory tract infection 9.6% nasopharyngitis 8.9% diarrhoea 6.9% NCT00856284 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 6.5% (placebo 1.1%) upper respiratory tract infection 5.4% (placebo 3.3%) blood triglycerides increased 2.2% (placebo 1.1%) NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy upper respiratory tract infection 3% (placebo 3.3%) blood triglycerides increased 2% (placebo 1.1%) urinary tract infection 2% (placebo 6.5%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 21.3% (placebo 1.1%) urinary tract infection 6.6% (placebo 6.5%) upper respiratory tract infection 3.3% (placebo 3.3%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination 25 mg hypertension 14.5% urinary tract infection 11.7% nasopharyngitis 11.6% NCT00306384 · Phase 3 · registry result, not featured evidence 12.5 mg hypertension 14.8% upper respiratory tract infection 11.6% urinary tract infection 11.1% NCT00306384 · Phase 3 · registry result, not featured evidence 25 mg QD hyperglycaemia 17% (placebo 26.4%) nasopharyngitis 6.3% (placebo 1.9%) headache 5.4% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence 12.5 mg BID hyperglycaemia 11.8% (placebo 26.4%) headache 4.5% (placebo 2.8%) creatinine renal clearance decreased 3.6% (placebo 3.8%) NCT01023581 · Phase 3 · registry result, not featured evidence alogliptin 12.5 mg BID + metformin 1000 mg BID creatinine renal clearance decreased 7.9% (placebo 3.8%) diarrhoea 7% (placebo 2.8%) dyspepsia 7% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination alogliptin 12.5 mg BID + metformin 500 mg BID hyperglycaemia 7.5% (placebo 26.4%) upper respiratory tract infection 7.5% (placebo 2.8%) headache 6.6% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 20% (placebo 4.2%) anaemia 12% (placebo 4.2%) constipation 8% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence 25 mg QD + 30 mg QD hypoglycaemia 13.6% (placebo 0%) nasopharyngitis 13.6% (placebo 4.2%) constipation 9.1% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence · combination Alogliptin 25 mg; Pioglitazone 30 mg; Metformin upper respiratory tract infection 7.2% nasopharyngitis 6.9% hypertension 5.9% NCT00432276 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 7% (placebo 4.7%) upper respiratory tract infection 6.2% (placebo 3.9%) abdominal pain upper 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence 12.5 mg hypertriglyceridaemia 5.5% (placebo 2.3%) hypertension 4.7% (placebo 3.1%) urinary tract infection 4.7% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence 25 mg + 15 mg influenza 6.2% (placebo 2.3%) nasopharyngitis 6.2% (placebo 3.9%) oedema peripheral 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 30 mg nasopharyngitis 6.9% (placebo 3.9%) back pain 6.2% (placebo 3.9%) influenza 6.2% (placebo 2.3%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 45 mg diarrhoea 5.4% (placebo 8.5%) headache 4.6% (placebo 4.7%) oedema peripheral 4.6% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 15 mg hypertension 6.9% (placebo 3.1%) nasopharyngitis 6.2% (placebo 3.9%) dizziness 5.4% (placebo 3.1%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg dizziness 3.8% (placebo 3.1%) nasopharyngitis 3.8% (placebo 3.9%) upper respiratory tract infection 3.8% (placebo 3.9%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 45 mg back pain 9.2% (placebo 3.9%) dizziness 4.6% (placebo 3.1%) headache 4.6% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 6.7% urinary tract infection 3% oedema peripheral 1.2% NCT00395512 · Phase 3 · registry result, not featured evidence 25 mg + 30 mg headache 12.2% back pain 6.1% urinary tract infection 5.5% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg headache 8.6% urinary tract infection 3.7% back pain 1.8% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 7% (placebo 6.2%) influenza 5.5% (placebo 4.1%) oedema peripheral 5.5% (placebo 7.2%) NCT00286494 · Phase 3 · registry result, not featured evidence 12.5 mg QD oedema peripheral 6.1% (placebo 7.2%) upper respiratory tract infection 5.6% (placebo 5.2%) nausea 4.5% (placebo 2.1%) NCT00286494 · Phase 3 · registry result, not featured evidence 25 mg QD diarrhoea 3.4% (placebo 5.8%) nasopharyngitis 3.4% (placebo 5.8%) bronchitis 2.9% (placebo 1.9%) NCT00286442 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 6.6% (placebo 3.8%) nasopharyngitis 5.6% (placebo 5.8%) upper respiratory tract infection 4.7% (placebo 6.7%) NCT00286442 · Phase 3 · registry result, not featured evidence 25 mg QD headache 5.6% (placebo 3%) hypertension 5.6% (placebo 2%) urinary tract infection 5.1% (placebo 3%) NCT00286468 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 4.4% (placebo 3%) diarrhoea 3.9% (placebo 0%) hypertriglyceridaemia 3.9% (placebo 2%) NCT00286468 · Phase 3 · registry result, not featured evidence 25 mg QD and 1-6 mg QD or BID nasopharyngitis 37.5% upper respiratory tract inflammation 10.5% fall 7.9% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 36.6% diabetic retinopathy 6.9% constipation 5.5% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 1-6 mg QD or BID nasopharyngitis 30.7% upper respiratory tract inflammation 6.7% back pain 5.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 31% back pain 6.3% headache 6.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 19.2% upper respiratory tract inflammation 11.5% back pain 3.8% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 19% gastroenteritis 3.8% upper respiratory tract inflammation 1.9% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 25 mg QD and Voglibose 0.2 mg TID nasopharyngitis 28.6% back pain 5.7% arthralgia 4.8% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID nasopharyngitis 35.2% upper respiratory tract inflammation 11.1% back pain 7.4% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 11.5% blood creatine phosphokinase increased 3.5% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 4.5% blood creatine phosphokinase increased 0% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 22.4% eczema 1.3% NCT01263483 · Phase 2/3 · registry result, not featured evidence 25 mg QD + 0.2 mg TID nasopharyngitis 16.5% eczema 0% NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 33% headache 7.2% upper respiratory tract inflammation 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 28.7% bronchitis 5.9% back pain 5% NCT01263496 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 35.1% blood creatine phosphokinase increased 8.2% back pain 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 30.2% upper respiratory tract inflammation 8.3% back pain 7.3% NCT01263496 · Phase 2 · registry result, not featured evidence 25 mg QD nasopharyngitis 12.5% (placebo 6.7%) headache 6.3% (placebo 5.3%) abdominal distension 3.8% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 8.3% (placebo 6.7%) flatulence 4.8% (placebo 2.7%) urticaria 3.6% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 10.1% (placebo 6.7%) blood creatine phosphokinase increased 5.1% (placebo 2.7%) abdominal distension 2.5% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 6.3% (placebo 6.7%) bronchitis 3.8% (placebo 1.3%) flatulence 2.5% (placebo 2.7%) NCT01263470 · Phase 2 · registry result, not featured evidence 25 mg QD headache 8.9% (placebo 7.3%) abdominal pain upper 6.7% (placebo 0%) dizziness 6.7% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 12.5 mg QD rash 9.1% (placebo 2.4%) abdominal pain 4.5% (placebo 0%) arthralgia 4.5% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 100 mg QD nausea 11.4% (placebo 0%) headache 9.1% (placebo 7.3%) urinary tract infection 9.1% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 50 mg QD diarrhoea 7% (placebo 7.3%) headache 7% (placebo 7.3%) urinary tract infection 7% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 6.25 mg QD urinary tract infection 7.1% (placebo 9.8%) abdominal pain upper 4.8% (placebo 0%) dizziness 4.8% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 25 mg rash papular 25% abdominal pain 0% blood creatine phosphokinase increased 0% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg blood creatine phosphokinase increased 14.3% haematocrit decreased 14.3% haemoglobin decreased 14.3% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg headache 18.2% fatigue 9.1% nausea 9.1% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg diarrhoea 20% neutrophil count decreased 20% pyrexia 20% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg abdominal pain 25% gastritis 12.5% headache 12.5% NCT00957268 · Phase 1 · registry result, not featured evidence headache 30% nausea 20% constipation 10% NCT01664624 · Phase 1 · registry result, not featured evidence · combination nausea 50% diarrhoea 40% vomiting 30% NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | n hypoglycaemia 22.7% (placebo 14.8%) upper respiratory tract infection 5.8% (placebo 9.1%) hyperglycaemia 5.6% (placebo 8.7%) NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 50 more resultshyperglycaemia 5.2% (placebo 14.7%) nasopharyngitis 5.2% (placebo 5.1%) NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 20.8% (placebo 12.1%) headache 15.6% (placebo 15.5%) blood ketone body increased 10.4% (placebo 3.4%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 hypoglycaemia 29.3% (placebo 28.8%) hypertension 6.2% (placebo 6.7%) hyperglycaemia 6% (placebo 6.9%) NCT01897532 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 33.8% (placebo 25.2%) viral upper respiratory tract infection 7.3% (placebo 5.3%) urinary tract infection 6.6% (placebo 6%) NCT02240680 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 38.5% (placebo 25.2%) viral upper respiratory tract infection 21.2% (placebo 5.3%) bronchitis 9.6% (placebo 2.6%) NCT02240680 · Phase 4 · registry result, not featured evidence infections 5.5% renal 4.7% surgical reintervention 4.7% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% musculoskeletal 1.1% skin 1.1% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination gastrointestinal 0% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination dorsal pain 5% (placebo 0%) nausea 5% (placebo 4.3%) toothache 5% (placebo 0%) NCT02350478 · Phase 4 · registry result, not featured evidence increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%) pneumonia 5.3% (placebo 0%) cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%) NCT01969084 · Phase 4 · registry result, not featured evidence 5 mg dyslipidaemia 14% hyperglycaemia 12.7% urinary tract infection 8.9% NCT01512979 · Phase 4 · registry result, not featured evidence 5 mg + Metformin dyslipidaemia 8.8% headache 6.3% urinary tract infection 6.3% NCT01512979 · Phase 4 · registry result, not featured evidence · combination 5 mg once daily + metformin once daily diarrhoea 18% abdominal pain 6.7% nausea 6.7% NCT01438814 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 17.3% (placebo 12.7%) upper respiratory tract infection 13.5% (placebo 12.7%) hyperuricaemia 5.8% (placebo 1%) NCT02897349 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 13.2% (placebo 5.6%) nasopharyngitis 7.1% (placebo 5.6%) upper respiratory tract infection 2.2% (placebo 5.1%) NCT01792518 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 5 mg diarrhoea 3% hyperuricaemia 3% dizziness 0% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperglycaemia 16.9% hyperuricaemia 5.6% nasopharyngitis 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperuricaemia 7.5% hyperglycaemia 4.8% upper respiratory tract infection 4.1% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD, then 2.5 mg / Metformin after week 12 hyperuricaemia 19.4% dizziness 6.5% hyperglycaemia 6.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg hyperuricaemia 6.2% hyperglycaemia 3.1% diarrhoea 1.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 5.6% hyperuricaemia 5.6% upper respiratory tract infection 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 9.5% hyperuricaemia 7.5% upper respiratory tract infection 7.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 500 mg BID upper respiratory tract infection 8.2% hyperuricaemia 5.4% diarrhoea 4.8% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 5 mg hyperglycaemia 10.4% nasopharyngitis 7.4% hypertension 6.7% NCT01183013 · Phase 3 · registry result, not featured evidence 5 mg + 15 mg / 5 mg + 30 mg diarrhoea 7.9% nasopharyngitis 7.1% back pain 6.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 30 mg oedema 9% dizziness 6.8% oedema peripheral 6.8% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 45 mg oedema peripheral 11.3% back pain 9% urinary tract infection 5.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 59.3% nasopharyngitis 18.6% hyperglycaemia 17.7% NCT01087502 · Phase 3 · registry result, not featured evidence 5 mg hyperlipidaemia 5.5% (placebo 3%) hyperglycaemia 2% (placebo 4%) NCT01214239 · Phase 3 · registry result, not featured evidence 5 mg once daily hyperglycaemia 4.9% (placebo 5%) hyperlipidaemia 4.4% (placebo 4%) diarrhoea 2.4% (placebo 1%) NCT01215097 · Phase 3 · registry result, not featured evidence 5 mg tablet anaemia 7.1% (placebo 6.7%) hyperglycaemia 6% (placebo 7.9%) hypoglycaemia 5.5% (placebo 4.5%) NCT00996658 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.2% back pain 5.9% constipation 5.9% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 36.6% bronchitis 11% arthralgia 6.1% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 45.5% pharyngitis 7.6% constipation 4.5% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 33.8% upper respiratory tract inflammation 8.1% arthralgia 5.4% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 31.5% hypoglycaemia 14% contusion 7% NCT01204294 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 6.6% (placebo 3.3%) hyperglycaemia 2.8% (placebo 9.2%) NCT01194830 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 30.3% (placebo 31.3%) hyperglycaemia 14.3% (placebo 17.8%) nasopharyngitis 11.3% (placebo 9.8%) NCT00954447 · Phase 3 · registry result, not featured evidence linagliptin 2.5 mg bid + metformin 1000 mg bid diabetes mellitus 9.9% diarrhoea 7% nasopharyngitis 7% NCT00915772 · Phase 3 · registry result, not featured evidence · combination linagliptin 2.5 mg bid + metformin 500 mg bid hyperglycaemia 12.9% diabetes mellitus 8% glomerular filtration rate decreased 6.2% NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 22.8% (placebo 16.5%) nasopharyngitis 10.5% (placebo 8.9%) diarrhoea 5.6% (placebo 2.5%) NCT01084005 · Phase 3 · registry result, not featured evidence hyperglycaemia 14.6% nasopharyngitis 9.9% dizziness 7.3% NCT00740051 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.3% (placebo 8.5%) upper respiratory tract infection 3.5% (placebo 7.7%) NCT00641043 · Phase 3 · registry result, not featured evidence · combination hyperglycaemia 8.6% (placebo 22.8%) NCT00621140 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 2/3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- eTreatment context has not been resolved for both arms.
- fAssessment timepoints differ: 52 weeks versus 26 weeks.
- gAssessment timepoints differ: 24 weeks versus 52 weeks.
- hThe reported result categories differ.
- iAssessment timepoints differ: 54 weeks versus 26 weeks.
- jAssessment timepoints differ: 26 weeks versus 16 weeks.
- kTrial phases differ: Phase 3 versus Phase 2.
- lAssessment timepoints differ: 432 weeks versus 52 weeks.
- mPopulation comparability has not been reviewed for 65 of these studies.
- nPopulation comparability has not been reviewed for 55 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alogliptin
show 5 more results
show 7 more results
show 9 more results
show 9 more results
show 9 more results
show 10 more results
show 18 more results
show 15 more results
show 15 more results
+ 47 further endpoints in the CSV export.
Linagliptin
show 12 more results
show 9 more results
show 1 more result
show 4 more results
show 1 more result
show 1 more result
+ 44 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Linagliptin's landscape